Bavarian Nordic’s Heery Joins Precision Bio as Chief Medical Officer

Christopher Heery has joined Precision BioSciences (NASDAQ: [[ticker:DTIL]]) as chief medical officer, the same position he held at his former company, Bavarian Nordic. Heery’s experience also includes time at the National Cancer Institute where he was head of the clinical trials group of the laboratory of tumor immunology and biology. Durham, NC-based Precision Bio completed a $126 million IPO in March to fund clinical tests of a cancer cell therapy developed with its proprietary gene-editing technology.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.